United Kingdom
Apoquel Logo

Dogs with atopic dermatitis treated with APOQUEL® experienced persistent improvement in skin lesions4


skin lesions assessed by dermatologists
In a randomised double-blinded study, 299 client-owned dogs with moderate to severe pruritus, and a history of chronic atopic dermatitis were treated with either APOQUEL® (n=152) or placebo (n=147).  Severity of dermatitis (CADESI-02)* was assessed by dermatologists before and after treatment throughout the 4 month study.


* CADESI-02: The Canine Atopic Dermatitis Extent and Severity Index is a scoring system used to assess canine atopic dermatitis severity. It is based on 3 parameters (erythema, lichenification and excoriation) and on the extent of the lesions. 40 body sites are evaluated.
** Open Label: Dogs with worsening pruritus and/or AD that had been on study to day 14 could be withdrawn and then enrolled in an open label study, in which every dog received APOQUEL® at a dose of 0.4–0.6 mg/kg once daily.4


apoquel® was evaluated in a long-term field study 10

  • This compassionate program was run involving 247 dogs at 26 sites in the US for dogs previously included in the field studies and in need of long term treatment with APOQUEL®

  • Dogs in the US compassionate program have been treated for a mean of 401 days (range 15-672) and assessed for long term safety and efficacy

  • Cystitis, vomiting, otitis, pyoderma and diarrhoea were the most frequently reported (>5% of dogs) side effects, reflecting short term study data. (See Safety)

  veterinary and dog